Bronchogen (Ala-Glu-Asp-Leu) is a synthesized tetrapeptide widely evaluated in preclinical respiratory models to investigate bronchial epithelial function and airway clearance mechanisms. Understanding procurement costs requires analyzing analytical verification standards, mass spectrometry profiling, and lot-specific purity metrics required for cell culture and ex vivo assays.
Bronchogen (Ala-Glu-Asp-Leu) is a synthesized tetrapeptide widely evaluated in preclinical respiratory models to investigate bronchial epithelial function and airway clearance mechanisms. Understanding procurement costs requires analyzing analytical verification standards, mass spectrometry profiling, and lot-specific purity metrics required for cell culture and ex vivo assays.
When evaluating the Bronchogen mucociliary clearance price for laboratory acquisition, principal investigators must consider the underlying analytical rigor, manufacturing origin, and quality verification standards that define peptide cost. Research-grade Bronchogen (Ala-Glu-Asp-Leu) utilized in mucociliary clearance assays generally varies in price depending on sequence purity, endotoxin quantification, and lot-specific analytical documentation. High-grade synthetic peptides designed for sensitive epithelial culture models demand specialized solid-phase peptide synthesis (SPPS) and rigorous purification protocols to ensure reliable in vitro performance.
Cheaper, unverified peptides frequently introduce confounding variables into mucociliary transport experiments due to residual trifluoroacetic acid (TFA) salts, truncated sequence impurities, or bacterial endotoxins. Securing high-purity material from established suppliers guarantees that experimental outcomes reflect true molecular interactions rather than artifacts from synthesis byproducts or biological contaminants.
Bronchogen is a short synthetic tetrapeptide consisting of L-alanine, L-glutamic acid, L-aspartic acid, and L-leucine (Ala-Glu-Asp-Leu). Belonging to the class of short bioregulatory peptides, Bronchogen's low molecular weight (446.45 g/mol) allows for high aqueous solubility and efficient cellular interaction within primary epithelial cultures. In preclinical research, this specific amino acid sequence is examined for its capacity to modulate chromatin architecture, influence gene expression pathways, and alter protein synthesis within bronchial tissues.
Researchers exploring pulmonary models utilize Bronchogen research peptides to examine targeted cellular pathways without the immunological complexity associated with larger recombinant proteins. Detailed structural characterization using high-resolution mass spectrometry ensures that the molecular mass matches theoretical calculations precisely, avoiding batch-to-batch structural variance during prolonged experimental timelines.
Mucociliary clearance represents a primary innate defense mechanism of the respiratory tract, driven by the coordinated beating of ciliated bronchial epithelial cells and the secretion of tracheobronchial mucus. In vitro data indicate that short peptide regulators like Bronchogen may interact with histone proteins and specific DNA sequences to regulate transcriptional activity associated with cytoprotection, mucin expression, and ciliary beat frequency.
Preclinical studies using cultured airway epithelial cells and rodent tissue explants suggest that exposure to Bronchogen influences the expression of tight junction proteins (such as zonula occludens-1 and occludin), supporting epithelial barrier integrity. Investigating these cellular mechanisms requires reliable experimental reagents, which can be sourced alongside other specialized compounds through the PX1 Research product catalog.
The baseline value of any research peptide compound is fundamentally tied to its analytical purity and verification procedures. Reverse-phase high-performance liquid chromatography (RP-HPLC) is the standard method used to measure chemical purity, establishing that the target sequence comprises at least 98% of the total peptide content. Mass spectrometry (MS) simultaneously confirms sequence identity by measuring exact molecular weight, ensuring the absence of deletion sequences or incomplete coupling products.
Every lot of Bronchogen provided by PX1 Research undergoes stringent third-party testing at an ISO 17025 accredited laboratory. Researchers can access a lot-specific Certificate of Analysis (COA) containing raw HPLC chromatograms and MS spectra, ensuring total transparency before initiating delicate cell culture protocols. Additional analytical parameters and testing protocols are detailed across our peptide research hub.
For researchers conducting mucociliary clearance studies using primary human bronchial epithelial cells (HBECs) or air-liquid interface (ALI) tissue models, endotoxin contamination presents a significant risk. Bacterial lipopolysaccharides (LPS) trigger inflammatory signaling cascades, altering ciliary beat dynamics, cytokine release profiles, and epithelial barrier resistance independently of the test peptide.
PX1 Research enforces strict endotoxin testing protocols (Chromogenic LAL Assay) to ensure endotoxin levels remain well below established threshold limits (<0.01 EU/mg). This rigorous quality control protects sensitive primary cell cultures from artifactual inflammatory responses, protecting the integrity of ex vivo mucociliary transport assays.
To understand the relative cost and specificity of Bronchogen within epithelial research, it is useful to compare it against other short bioregulatory peptides evaluated in similar tissue models. For instance, Cartalax (Ala-Glu-Asp) is a tripeptide studied primarily in connective tissue and chondrocyte extracellular matrix models, whereas Vilon (Lys-Glu) is a dipeptide evaluated for immunomodulatory and fibroblast activity. Additionally, Pineson is investigated for neuroprotective and cellular aging pathways.
While these compounds share a common short-chain peptide framework developed to study nuclear chromatin interactions, Bronchogen's specific tetrapeptide sequence (Ala-Glu-Asp-Leu) targets pulmonary and bronchial epithelial gene expression profiles. Researchers designing comparative organ-specific experiments often source these distinct bioregulators simultaneously via bulk lab accounts to optimize volume pricing and standardize experimental controls.
Several critical manufacturing and operational variables influence the price of research-grade Bronchogen. Understanding these metrics helps laboratory procurement managers evaluate value beyond raw unit cost:
1. Synthesis Scale & Coupling Efficiency: Solid-phase peptide synthesis requires high-purity amino acid precursors and optimized coupling reagents to prevent racemization.
2. Multi-Step Purification: Achieving >98% HPLC purity requires repeated preparative RP-HPLC passes, yielding a refined final product but increasing processing time.
3. Independent Analytical Validation: Comprehensive third-party verification via mass spectrometry, HPLC, and endotoxin assays adds verification overhead that protects downstream data.
4. Controlled Storage and Packaging: Lyophilization under sterile conditions followed by argon flushing and temperature-controlled storage prevents oxidation and moisture degradation during transport.
By maintaining USA-based manufacturing facilities operating under strict quality management standards, PX1 Research provides fully traceable, high-purity peptides that reduce experimental failure rates and sample waste.
To preserve structural stability and prevent premature degradation, lyophilized Bronchogen must be handled according to strict laboratory protocols. Upon receipt, the peptide vial should be allowed to equilibrate to room temperature inside a desiccator before opening to prevent atmospheric moisture condensation on the cake.
Reconstitution should be performed using sterile, endotoxin-free water or phosphate-buffered saline (PBS, pH 7.4), depending on assay parameters. For long-term stock solutions, aliquoting reconstituted Bronchogen into sterile polypropylene vials and storing at -80°C minimizes freeze-thaw cycles, preserving peptide integrity for subsequent mucociliary transport assays. Further handling methodologies can be explored in our specialized guide on bronchial epithelial models.
Lyophilized Bronchogen exhibits excellent physical and chemical stability when stored under appropriate environmental conditions. Unreconstituted vials stored at -20°C or -80°C remain stable for extended periods, shielded from light exposure to prevent potential photo-oxidation of peptide bonds.
Once reconstituted, aqueous solutions should be used promptly or frozen immediately. Repeated freeze-thaw cycles must be strictly avoided, as thermal fluctuations can induce peptide aggregation or partial hydrolysis, altering concentration accuracy in delicate tissue culture systems.
Selecting a research peptide supplier requires evaluating supply chain security, lot-to-lot consistency, and manufacturing transparency. PX1 Research manufactures all research compounds within state-of-the-art USA facilities adhering to cGMP-compliant processes and ISO 17025 testing protocols. Orders ship directly from regional centers in California and Arizona, utilizing same-day dispatch for orders placed before daily cutoff times.
By eliminating international supply chain uncertainties and unverified third-party re-sellers, PX1 Research delivers fully documented, highly purified Bronchogen for advanced mucociliary clearance and respiratory tissue research.
What factors determine the Bronchogen mucociliary clearance price for research labs?
The price of Bronchogen is determined by synthesis scale, RP-HPLC purity levels (>98%), mass spectrometry identity verification, chromogenic endotoxin testing (<0.01 EU/mg), and third-party ISO 17025 analytical documentation.
Is Bronchogen supplied for human clinical use or therapeutic application?
No. Bronchogen is supplied strictly as a research-grade compound for in vitro laboratory assays, cellular tissue culture, and preclinical animal models. It is not intended for human or veterinary medical use.
What is the sequence and molecular weight of Bronchogen?
Bronchogen is a synthetic tetrapeptide with the amino acid sequence L-Ala-L-Glu-L-Asp-L-Leu (Ala-Glu-Asp-Leu) and a theoretical molecular mass of 446.45 g/mol.
How is Bronchogen purity verified by PX1 Research?
Every lot of Bronchogen is verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for chemical purity and Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular mass confirmation, with results published on lot-specific COAs.
Why is endotoxin testing critical for Bronchogen mucociliary assays?
Primary bronchial epithelial cell cultures are highly sensitive to lipopolysaccharides (LPS). Endotoxin levels above 0.01 EU/mg can trigger inflammatory cytokine release and alter ciliary beat frequency, confounding experimental results.
How should lyophilized Bronchogen be stored in the laboratory?
Lyophilized Bronchogen should be stored at -20°C or -80°C in a dry, dark environment. Reconstituted stock solutions should be aliquoted and frozen to avoid multiple freeze-thaw cycles.
What diluents are recommended for reconstituting Bronchogen for in vitro assays?
Sterile, endotoxin-free water or sterile phosphate-buffered saline (PBS, pH 7.4) are standard diluents for reconstituting Bronchogen for cellular assays.
What related short peptides are evaluated alongside Bronchogen in research?
Researchers frequently compare Bronchogen with other short bioregulatory peptides such as Cartalax (Ala-Glu-Asp), Vilon (Lys-Glu), and Pineson in comparative tissue-specific gene expression studies.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.